Allergy Therapeutics plc
AGYTF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 22.1% | 57.3% | -35.6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 32.8% | 61.3% | 42.6% | 61.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -87.3% | -12.2% | -105.5% | -27.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -96% | -32.6% | -113.6% | -46.6% |
| EPS Diluted | -0.008 | -0.002 | -0.005 | -0.006 |
| % Growth | -265.2% | 55.8% | 10.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |